Comparison of the safety and prognosis of sequential regorafenib after sorafenib and lenvatinib treatment failure in patients with unresectable hepatocellular carcinoma: a retrospective cohort study

• DOI: 10.21037/jgo-22-404
• Publication Date: 2022-06-29T04:02:51Z
• Authors: Jian Zhai; Jianwei Liu; Zhigang Fu; Shilei Bai; Xiaowei Li; Zengqiang Qu; Yanfu Sun; Ruiliang Ge; Feng Xue
• Keywords: Lenvatinib; Regorafenib

There is lack of studies on sequential regorafenib after sorafenib and lenvatinib treatment failure in patients with unresectable hepatocellular carcinoma (HCC). This study was to explore the safety prognosis HCC patients.This a retrospective, real-world that included 50 who received regrafinib failure. The two groups were compared.The incidence all grade III/IV adverse events 68% 24%. According Response Evaluation Criteria Solid Tumours (RECIST) 1.1 modified (m) RECIST standards, objective response rates (ORRs) receiving 14.0% 22.0%, respectively. disease control (DCRs) 62.0% 60.0%, Based different first-line targeted drugs, divided into (n=22) group (n=28). no differences between except age bilirubin. And there other treatments before or regorafenib. baseline basically same had good comparability. difference events, ORR DCR (P>0.05). On long-term prognosis, total overall survival (TOS) 23.0 (95% CI: 15.1-30.9) vs. 29.7 21.4-38.1) months. statistically significant (P=0.041). Besides, (ROS) 11.7 7.1-16.3) 15.9 8.3-23.5) ( P=0.045). progression-free (RPFS) 5.6 1.9-9.2) 8.0 5.1-10.9) months group, respectively, not (P=0.380).Regorafenib an effective drug for second-line HCC, fewer severe 14-22% 62-60%, Both TOS ROS better than those group. For whose lenvatinib, it safe accept progresses.